Odronextamab ASH Presentations Underscore Impressive Potential in Earlier Lines of Treatment and Additional Types of Lymphoma

New data for odronextamab presented at ASH 2024 show potential in earlier lines of treatment and additional types of lymphoma, including complete responses in follicular lymphoma and durable responses in diffuse large B-cell lymphoma progressing after CAR-T therapy.